1-3 of 3
Sally Lanar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic
Journal: Blood
Blood (2023) 142 (Supplement 1): 7352.
https://doi.org/10.1182/blood-2023-178858
Published: 2023
Journal Articles

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Tanya Siddiqi, Ulrich Jaeger, Olga Moshkovich, Julia Braverman, Fei Fei Liu, Sally Lanar, Matthew Miera, Selam Shah, Jennifer Devlen, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4098.
https://doi.org/10.1182/blood-2021-151823
Published: 2021
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Nina Shah, Michel Delforge, Paula Rodríguez-Otero, Olga Moshkovich, Julia Braverman, Devender Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B. Campbell, Nikhil C. Munshi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2021-145166
Published: 2021